Reductions in Cardiovascular Disease Risk with Icosapent Ethyl Therapy: Sub-analyses from REDUCE-IT Trial

Amarin Corporation presented new analyses from the REDUCE-IT trial at the ESC 2025 Congress. The data showed that VASCEPA/VAZKEPA (icosapent ethyl) therapy resulted in a 9% reduction in total hospitalizations and reduced cardiovascular disease risk in certain high-risk patient subgroups, including those with cardiovascular-kidney-metabolic syndrome and high levels of apolipoprotein B and fasting triglyceride rich lipoprotein cholesterol. The 2025 ESC/EAS Dyslipidemia Guideline Focused Update reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy in high-risk or very high-risk patients based on the REDUCE-IT trial.